glp 1 drugs and dementia Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease Parkinson's disease | Journal of Biomedical Science Adults whose type 2 diabetes

As evidence accrues, we, and others, will monitor what it means for the impact of GLP-1 medications on SMM, but so far we have not seen any compelling clinical data (although new systematic reviews and meta analyses have been proposed ) that GLP-1 medications lead to pathological skeletal muscle mass loss relative to what has been demonstrated and observed in other weight loss interventions

Liraglutide administration is recommended once daily, with a Tmax of 913 hours and t1/2 of 13 hours

Therefore, drugs used for treatment of diabetes are expected to have a preventive effect against Alzheimer's disease

Heres What to Know

[DOI] [PMC free article] [PubMed] [Google Scholar] 6.Mailhac A., Pedersen L., Pottegrd A., Sndergaard J., Mogensen T., Srensen H.T., Thomsen R.W

10.3389/fendo.2024.1330936 Front